Reference:
1. Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatol Treat 2004;15(3):146–152
2. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13: 191–211.
3. Misiak-Galazka M, Wolska H, Galazka A, Kwiek B, Rudnicka L. General characteristics and comorbidities in patients with palmoplantar pustulosis. Acta Dermatovenerol Croat. 2018;26(2):109–18
4. Marzano AV, Cugno M, Trevisan V et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010; 162: 100–107.
5. Guenova E, Teske A, Fehrenbacher B et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147: 1203–1205.
6. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20: 845–847.
7. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165:1244–1250.
8. Kameyama H, Akagane Y, Kawada A, Tezuka T. A case of palmoplantar pustulosis associated with pyoderma gangrenosum. Hifunokagaku 2003; 2: 526–531.
9. Ogasawara K. Pyoderma gangrenosum associated with palmoplantar pustulosis (original title in Japanese). Nihon Rinsho Hifuka Ikai Zasshi 2006; 23: 136–138
10. Ohtsuka M and Yamamoto T. Association of pyoderma gangrenosum and palmoplantar pustulosis: A case report and review of the previous works. Journal of Dermatology 2014; 41: 732–735
11. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 2012; 132:2166–70
12. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998; 138:390–8.
13. Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. Br J Dermatol 1996;134;1079–82.
14. Hiraiwa T, Yamamoto T. Nail involvement associated with palmoplantar pustulosis. Int J Dermatol. 2017;56(2): e28–9
15. Nguyen MT, Borchers A, Selmi C, et al. The SAPHO syndrome. Semin Arthritis Rheum 2012; 42:254–65
16. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010; 62: 646–654.
17. Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163:1116–18.
Figures:
Figure 1(a) (10X) H & E stain showing hemorrhagic ulcer (black arrows) adjoining an intact epidermis with large necrotizing suppurative dermal inflammation (white arrows) (b) (40X) H & E stain showing dense neutrophilic infiltrate in the dermis with extravasation of Red blood cells (c) (40X) H & E stain (red arrows) showing endothelial swelling with neutrophilic infiltration of blood vessel wall
Figure 2 (a and b) showing irregular undermined ulcer with atrophic plaque on dorsum of left foot, (c and d) erythematous plaque with yellow brown crust, (e and f) onycholysis and subungual hyperkeratosis, (g and h) 1 week after starting treatment, (I and j) 4 weeks after starting treatment and (m, n, o and p) 9 months after stopping the treatment
Figure 3(a) (10X) H & E stain showing hyperkeratosis with parakeratosis with munro’s micro abscess (black arrows) with hypogranular layer (white arrow) with psoriasiform hyperplasia of epidermis (red arrow) (b) (10X) H & E stain showing munro microabscess with underlying hypogranular layer (c) 100X magnification showing neutrophil and neutrophilic dusts in stratum corneum (munro microabsess)